Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings: These 5 analysts have an average price target of $7.2 versus the current price of Invitae at $2.675, implying ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock ...

Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

Biotech InVitae Corp (NYSE:NVTA) is down 2.3% this afternoon -- set to snap its three day win streak -- though the catalyst is unclear. Prior to today's drop, the equity was recovering from its early ...

The stock's recent peak comes amid historically low implied volatility The shares of InVitae Corp (NYSE: NVTA) are down 7.6% to trade at $34.23 at last check, just one day after hitting a record high ...